Introduction of the new triazole antifungal drug posaconazole and voriconazole
LIU Jie;HU Xiao-Ping;LIU Wei;Department of Dermatology & Venereology, Peking University First Hospital,Research Center for Medical Mycology,Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Peking University;Department of Dermatology & Venereology, Peking University Shenzhen Hospital;
The morbidity and mortality of invasive fungal infection is increasing year by year, and more and more new antifungal drugs are produced to the public. Posaconazole and voriconazole, having strong antifungal activity in vivo and vitro, are new spectral triazole drugs for the treatment and prevention of invasive fungal infections. They have the same mechanism of action and each owns characteristics in antifungal activity, drug metabolism and safety. Posaconazole and voriconazole are superior to the originally practical drugs itraconazole and fluconazole in molecular structure, having stronger and wider antifungal spectrum. The development and application of the two new drugs suggest that the research on antifungal drugs trends towards the obtainment of high efficiency, broad spectrum and low toxicity. The clinical research and blood concentration monitoring of the two drugs are still to be further explored. This paper reviews their molecular structures, action mechanism, clinical indications and pharmacokinetics. The future clinical application perspective of the two drugs is predicted.